We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sony DADC BioSciences and TSMC Receive AACC Award

By LabMedica International staff writers
Posted on 29 Jul 2014
The American Association for Clinical Chemistry (AACC) presented Sony DADC BioSciences and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC; Hsinchu, Taiwan) with the AACC Industry Division Award.

The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.

The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.

The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.

Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.

Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”

Related Links:

Sony DADC BioSciences
TSMC


New
Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5

Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
ADLM